Ophthalmology biotech PulseSight Therapeutics has confirmed the closure of its Series A funding round, the proceeds of which will be used to fund a phase 1 study into its dry age-related macular degeneration (AMD) therapy, PST-611. The funding round was supported by existing investor Pureos BioVentures.

Paragon Bioscience’s clinical biopharma spin-out, Emalex Bioscience, has announced that its lead candidate for the treatment of Tourette syndrome has met its primary and secondary endpoints in a recent phase 3 study.

Recce Pharmaceuticals has announced positive patient data from its phase 2 clinical trial into RECCE 327 (R327), for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), including diabetic foot infections (DFI).

Real-world data into a mandatory non-medical switching policy for patients with inflammatory bowel disease (IBD) has shown long-term safety and efficacy. The patients transitioned from using adalimumab (Humira) to a biosimilar due to the enaction of the policy in British Columbia, Canada – the first Canadian province to do so.

Aplagon, a clinical stage biopharmaceutical company dedicated to the development of first-in-class therapeutics for thrombo-inflammatory diseases, has announced the closing of a €7m financing round for the initiation of phase 2a of its clinical trials.

Swedish biopharmaceutical company AnaCardio has announced the completion of a Series A extension financing round that has raised $19m for its novel contractile agents. The round was co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures.

Beckley Psytech Ltd, a clinical-stage biopharmaceutical company that specialises in the production of accessible medicines for mental health conditions, has announced positive results for the phase 2a study into BPL-003 in patients with moderate-to-severe alcohol use disorder (AUD).

Novadip Biosciences, a clinical stage biotechnology company with a specialty in regenerative medicine, has announced the results of its 12-month post-surgical visit as part of phase 1b/2a of the NCT05693558 trial.

French biotech AdipoPharma has announced that it has secured funding for a clinical trial into its type 2 diabetes therapeutic, PATAS.

Global biopharma company GSK has announced positive phase 3 results for its cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) treatment, linerixibat, which is currently being studied in the GLISTEN trial.

Puma Biotechnology has announced the initiation of its alisertib in cancer (ALISCATM-Breast1) phase 2 trial of alisertib in combination with endocrine therapy. Based on the outcomes of the trial, the company anticipates to meet with the US Food and Drug Administration (FDA) regarding an approval pathway.

UK-based Barinthus Biotherapeutics has announced data from its ongoing phase 2b HBV003 clinical trial, which was presented at the American Association for the Study of Liver Diseases (AASLD) Meeting 2024.